ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

obexelimab

Also written as “Obexelimab” and “XmAb5871”.

Its studies are mostly in Lupus Erythematosus, Systemic · Immunoglobulin G4-Related Disease · Multiple Sclerosis · Anemia, Hemolytic, Autoimmune, led by 2 companies.

Drug pageObexelimab: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 14, 20227 company-led studies, 4 open or runningLicense: Xencor → Zenas BioPharma, Nov 2021

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zenas BioPharma (USA)44 open or runningphase 3since Dec 14, 2022Dec 14, 2022none ahead
Xencorits history only30 open or runningphase 2since Jan 8, 2016Jan 8, 2016none ahead
  • Named in bristol myers squibb’s own pipeline as obexelimab, phase 4, as of Oct 29, 2026 (source).

Also a collaborator on its studies: Bristol-Myers Squibb, PPD DEVELOPMENT, LP, ICON and Parexel.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Zenas BioPharma (USA) only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2018Named obexelimabINNProposed as its International Nonproprietary Name in WHO's List 119
  2. Nov 21, 2021Zenas BioPharma licensed it from XencorLicenseWorldwide rights · announced · Zenas BioPharma and Xencor (release)
  3. Dec 14, 2022First study: phase 3 study in Immunoglobulin G4-Related DiseaseFirst studyNCT05662241 · 194 enrolled · United States, Argentina, Canada and more
  4. Mar 13, 2023Phase 3 study in Warm Autoimmune Hemolytic AnemiaNCT05786573 · 134 enrolled · Italy, Poland, Spain and more
  5. Aug 14, 20242 phase 2 studiesNCT06559163, NCT06564311

TargetBeta

“A humanized immunoglobulin G1 (IgG1) noncytolytic monoclonal antibody directed against the B-cell-specific cell surface antigen CD-19, Fc-engineered for increased affinity to Fc gamma receptor IIB (FcgRIIB; CD32B), with potential immunomodulatory activity. Upon administration, obexelimab simultan…”NCIt, read by Claude

Studies

All 4 Zenas BioPharma (USA) leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06564311Multiple Sclerosis · United States, Austria, Belgium and more2Active, not recruitingAug 28, 202593
NCT06559163Lupus Erythematosus, Systemic · United States, Belgium, Bulgaria and more2Active, not recruitingSep 23, 2026190
NCT05786573Warm Autoimmune Hemolytic Anemia · Italy, Poland, Spain and more3Active, not recruitingJun 30, 2026134
NCT05662241Immunoglobulin G4-Related Disease · United States, Argentina, Canada and more3Active, not recruitingNov 13, 2025194

How it is read

Names in the registry

  • “Obexelimab”, 5 entries
  • “XmAb5871”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.